Orion
44,78
EUR
+0,43 %
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
13.895 følger denne virksomhed
+0,43%
+4,68%
+7%
-6,92%
+8,9%
+4,77%
+27,04%
+5,44%
+298,75%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Læs mereMarkedsværdi
6,32 mia. EUR
Aktieomsætning
867,6 t EUR
P/E (adj.) (24e)
20,19
EV/EBIT (adj.) (24e)
15,91
P/B (24e)
6,46
EV/S (24e)
4,23
Udbytteafkast, % (24e)
3,68 %
Finanskalender
25.2
2025
Årsrapport '24
3.4
2025
Generalforsamling '25
23.4
2025
Delårsrapport Q1'25
Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper
Orion and Marinus terminate agreement for ganaxolone in Europe
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Drug development investment: Value creation through M&As and licensing agreements
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
Regulation of drug development
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
142,701 Orion Corporation A shares converted into B shares
Orion Research Foundation grants EUR 1,109,000 for research in 2025
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
Orion Corporation: Managers’ transactions – Henrik Stenqvist
